Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma

Figure 2 The mutation landscape of cyclin dependent kinase inhibitor 2A in hepatocellular carcinoma based on cBioPortal database. A: OncoPrint plot indicated different types and proportions of cyclin dependent kinase inhibitor 2A (CDKN2A) mutations; B and C: The association between CDKN2A copy number and mRNA expression are shown in the dot plot (B) and correlation plot (C); D: Demonstration of mutation sites, mutation types, and mutation cases on the two-dimensional structure of the CDKN2A protein; E: The cell cycle pathway mapper of CDKN2A in hepatocellular carcinoma. CDKN2A: Cyclin dependent kinase inhibitor 2A.